The Encapsulation of Lycopene in Nanoliposomes Enhances Its Protective Potential in Methotrexate-Induced Kidney Injury Model

Table 4

Kidney oxidative status in animals after different experimental treatments.

Group/parameter	CAT (IU/mg proteins)	MPO (OD/mg proteins)	AOPP (μmol/mg proteins)	MDA (nmol/mg proteins)	NO (μmol/l)
Control (corn oil treated)	120 ± 2.1	111 ± 4.6	13.5 ± 4.9	10.2 ± 0.6	26.5 ± 5.7
Lycopene	115 ± 3.2	99.5 ± 21.9	12.9 ± 4.3	11.2 ± 1.9	29.5 ± 10.0
Empty nanoliposomes	114 ± 1.3	117.5 ± 6.3	14.2 ± 0.9	11.3 ± 1.4	31.6 ± 7.8
Lycopene nanoliposomes	120 ± 3.5	119 ± 1.4	12.9 ± 1.6	9.9 ± 0.5	30.6 ± 2.8
Methotrexate	24.5 ± 7.5^a	189 ± 2.3^a	29.6 ± 6.1^a	27.9 ± 0.4^a	65.6 ± 5.8^a
Lycopene + methotrexate	67.1 ± 2.1^a,b	159 ± 11.3^a,d	21.2 ± 0.4^a,d	17.8 ± 2.2^a,b	41.9 ± 11.5^b,e
Empty nanoliposomes + methotrexate	30 ± 4.3^a	170 ± 13.8^a	28.9 ± 2.6^e	25.9 ± 1.6^a,	66.3 ± 3.5 ^a
Lycopene nanoliposomes + methotrexate	83.1 ± 3.2^a,b,c	141.5 ± 14^a,b	17.9 ± 1.8^b	14.6 ± 2.4^a,b,f	39.3 ± 1.4^b,c,e

^a versus control group treated with corn oil; ^b versus methotrexate group; ^c versus lycopene + methotrexate group; ^d versus methotrexate group; ^e versus control group treated with corn oil; ^f versus lycopene + methotrexate group